Dysfunction of Respiratory Enzymes in Adults With Mental Illness (DREAM)

What Was Tested

This registered not phased trial tested Methylene blue (non-peptide stack partner).

This study tested whether intravenous methylene blue changes brain activity during a working-memory task differently in adults with schizophrenia taking stable antipsychotic medication and healthy volunteers.

Each participant received methylene blue and a placebo solution with no methylene blue at separate visits and completed the task during functional magnetic resonance imaging (fMRI).

It had two arms (groups): Placebo first drug second (experimental) and Drug first placebo second (experimental).

Placebo first drug second.

Drug first placebo second.

The registry classes the interventions as drug.

Who Took Part

The registry lists 53 actual participants took part.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Aged 18 to 65 years. Able to provide informed consent and have an adequate command of English. For participants in the schizophrenia group: diagnosis of schizophrenia according to DSM-5 criteria. For control participants: no current or past mental disorder. For control participants: no family history of schizophrenia or psychosis.

The full record lists 18 inclusion and 0 exclusion criteria.

How the Study Was Run

The set-up was non-randomized, crossover and double-blind.

In the crossover set-up each of the participants took both Methylene blue (non-peptide stack partner) and the comparison in turn, acting as their own control.

As a double-blind Methylene blue (non-peptide stack partner) study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and outcomes assessor.

It started in 2020-06-01 with completion listed for 2025-08-31.

It ran at 1 site in United Kingdom.

Its stated primary purpose is other.

What Was Measured

Primary outcome: FMRI BOLD response (time frame: Day 1 [on day of drug/placebo administration]).

What This Means in Plain Language

Put simply, this is a not phased, non-randomized trial of Methylene blue (non-peptide stack partner) in 53 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.